CRVSCorvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the Un…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company’s oral ITK inhibitor, is now being tested across five different diseases at once, from a rare blood cancer to asthma. That kind of breadth from a single-asset biotech is either a […] | IInsider Monkey | |
 Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript Soquelitinib advances across multiple indications, with cash runway extended into 2028. | ||
Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ... Corvus Pharmaceuticals Inc (CRVS) reports robust financials and progresses key clinical trials for soquelitinib across multiple indications. | ||
 Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary Moby summary of Corvus Pharmaceuticals, Inc.'s Q2 2026 earnings call | ||
 Corvus Pharmaceuticals Q2 Earnings Call Highlights Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected milestones across programs in peripheral T-cell lymphoma, atopic dermatitis, hidradenitis suppurativa and | ||
IInsider Monkey | ||